Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection

Pediatrics International

Volumn 41, Issue 3, 1999, Pages 270-273

  Helvaci, Mehmet ^a,b   Özkaya, Buket ^a   Özbal, Ebru ^a   Özinel, Sema ^a   Yaprak, Işin ^a  

^a SSK Tepecik Teaching Hospital   (Turkey)

^b Inönü Cad No 400/15 ^*  (Turkey)

Author keywords

Childhood; Chronic hepatitis B; Fibronectin; Interferon

Indexed keywords

ALPHA2B INTERFERON; FIBRONECTIN;

ADOLESCENT; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SERODIAGNOSIS; TREATMENT OUTCOME; VIRUS INHIBITION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRONECTINS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0033017568     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.1999.01066.x     Document Type: Article

References (15)

1. 1 Mossesson MW, Amrani OL. The structure and biological activities of plasma fibronectin. Blood 1980; 56: 145-8.
2. 2 McCafferty MH, Lepow M, Saba TM et al. Normal fibronectin levels as a function of age in the pediatric population. Pediatr. Res. 1983; 17: 482-5.
3. 3 Mosher DF. Physiology of fibronectin. Ann. Rev. Med. 1984; 35: 561-5.
4. 4 Proctor RA. Fibronectin: A brief overview of its structure, function and physiology. Rev. Infect. Dis. 1987; 9: 317-21.
5. 5 Mosher DF, Williams EM. Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J. Lab. Clin. Med. 1978; 91: 729-35.
6. 6 McGavin MH, Krajewska-Pietrasik D, Ryden C. Identification of a Staphylococcus aureus extracellular matrix binding protein with broad specificity. Infect. Immun. 1993; 61: 2479-85.
7. 7 Saba TM, Albert W, Blumenstock FA, Evanega G, Staehler F, Cho E. Evaluation of a rapid immunoturbidimetric assay for opsonic plasma fibronectin in surgical and trauma patients. J. Lab. Clin. Med. 1981; 98: 482-91.
8. 8 Weigand K, Zaugg PY, Frei A, Zimmermann A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984; 4: 835-8.
9. 9 Gabrielli GB, Casarili M, Bonazzi L, Baracchino F, Bellisola G, Corocher R. Plasma fibronectin in liver cirrhosis and its diagnostic value. Clin. Chim. Acta 1986; 160: 289-96.
10. 10 Yamauchi M, Nakajima H, Ohata M et al. Detection of fibronectin receptor in sera: Its clinical significance as a parameter of hepatic fibrosis. Hepatology 1991; 14: 244-50W.
11. 11 Simon K, Zalawska M, Gladysz A, Rotter K, Piszko P, Glowacki A. Plasma fibronectin in chronic liver disease marker of fibrosis? Przegl Lek. 1995; 52: 129-132 (in Polish).
12. 12 Irshad M, Acharya SK, Joshi YK, Tandon BN. Role of fibronectin and complement in immunopathogenesis of acute and subacute hepatic failure. J. Gastroenterol. Hepatol. 1994; 9: 355-60.
13. 13 Di Bisceglie AM. Interferon therapy for chronic viral hepatitis. N. Engl. J. Med. 1994; 330: 137-41.
14. 14 Kagowa T. A pilot study of long term weekly interferon B administration for chronic hepatitis B. Am. J. Gastroenterol. 1993; 88: 212-16.
15. 15 Tomihira N. Changes in plasma, vitronectin, fibronectin and serum laminin PI levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases. Fukuoka Igaku Zattusshi 1991; 82: 21-30 (in Japanese).